Simpson, Eric L. http://orcid.org/0000-0003-0853-0252
Lockshin, Ben http://orcid.org/0000-0001-9256-1814
Lee, Lara Wine http://orcid.org/0000-0001-6739-4508
Chen, Zhen
Daoud, Moataz
Korotzer, Andrew
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals
Article History
Received: 21 August 2023
Accepted: 19 October 2023
First Online: 4 January 2024
Change Date: 9 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13555-024-01118-y
Declarations
:
: The PROSE study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guideline, and applicable regulatory requirements, and received institutional review board/ethics committee approval. All patients provided informed consent, and data were anonymized in compliance with the Health Insurance Portability and Accountability Act (HIPAA) inserted by journal.
: Eric Simpson receives/has received grants/research support from AbbVie, Acrotech Biopharma Inc., Amgen, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Castle Biosciences, CorEvitas, Dermavant Sciences, Dermira, Eli Lilly and Company, Incyte, Kymab, Kyowa Kirin, National Jewish Health, LEO Pharma, Pfizer, Regeneron Pharmaceuticals, Sanofi, and Target RWE; and is/has been a consultant for Advances in Cosmetic and Medical Dermatology Hawaii LLC, AbbVie, Amgen, AOBiome LLC, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharmaceuticals, Boehringer Ingelheim USA, Inc., Boston Consulting Group, Bristol Myers Squibb, Collective Acumen LLC (CA), CorEvitas, Dermira, Eli Lilly and Company, Evelo Biosciences, Evidera, Excerpta Medica, FIDE, Forte Biosciences, Galderma, GlaxoSmithKline, Incyte, Janssen, Johnson & Johnson, Kyowa Kirin Pharmaceutical Development, LEO Pharma, Medscape LLC, Merck, MauiDerm, MLG Operating, MJH Holdings, Pfizer, Physicians World LLC, PRImE, Regeneron Pharmaceuticals, Revolutionizing Atopic Dermatitis Inc., Roivant, Sanofi-Genzyme, Trevi Therapeutics, Valeant Pharmaceuticals, Vindico Medical Education, and WebMD. Ben Lockshin has received investigator and speaker fees from Eli Lilly and Regeneron Pharmaceuticals Inc.; investigator fees from Anacor Pharmaceuticals, Dermira, Franklin Bioscience, and LEO Pharma; and investigator/speaker/consultant fees from AbbVie. Lara Wine Lee is on the Advisory Board of Castle Creek, Eli Lilly, Pfizer, Regeneron Pharmaceuticals Inc., and Verrica; is a consultant for AbbVie, Amryt, Krystal Biotech, Novartis, and Kimberly Clark; is/has been an investigator for AbbVie, Amgen, Amryt, Arcutis, Castle Creek, Celgene, Eli Lilly, Galderma, Incyte Corp, Mayne Pharmaceuticals, Moonlake Pharmaceuticals, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, Target Pharma, Timber Pharmaceuticals, Trevi Therapeutics, and UCB; and has received speaker fees from Amryt and Krytsal Biotech. Moataz Daoud is a Sanofi employee and may hold stock and/or stock options in the company. Zhen Chen and Andrew Korotzer are employees and shareholders of Regeneron Pharmaceuticals Inc.